Dublin, July 03, 2020 (GLOBE NEWSWIRE) -- The "Progressive supranuclear palsy (PSP) - Market Insights, Epidemiology and Market Forecast-2030" drug pipelines has been added to ResearchAndMarkets.com's ...
Progressive supranuclear palsy (PSP) is a rare brain disorder that affects approximately 6 in 100,000 people worldwide. It causes muscle weakness and affects gait, balance and overall movement, as ...
Dublin, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The "Progressive Supranuclear Palsy (PSP) Therapies Market by Type of Treatment (Curative and Palliative / Symptomatic), and Key Geographical Regions (US, UK, ...
BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study ...
What is progressive supranuclear palsy (PSP)? Progressive supranuclear palsy (PSP) is a condition that causes both dementia and problems with movement. It is a progressive condition that mainly ...
Progressive supranuclear palsy (PSP) is a rare brain disorder that affects approximately 6 in 100,000 people worldwide. It causes muscle weakness and affects gait, balance and overall movement, as ...
Progressive supranuclear palsy (PSP) is a rare brain disorder. It causes serious and permanent problems with control of gait (walking) and balance. The most obvious sign of the disease is when you can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback